ALNOV:EPA
Novacyt SA
0,41 €
0,00%
(0,00) 1 d.
6. nov., 17:35:21 GMT+1 · EUR
search
Visi simboli
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: ALNOV…
Atvērt
0,41 €
Augsta
0,41 €
Zema
0,40 €
Tirgus kapitalizācija
27,19 milj.
Vid. apjoms
187,71 tūkst.
Apjoms
119,78 tūkst.
Augstākā 52 ned.
1,04 €
Zemākā 52 ned.
0,29 €
Peļņa uz vienu akciju
-0,38 €
Apgrozībā esošās akcijas
72,59 milj.
Darbinieku skaits
228
Atvērt
0,41 €
Augsta
0,41 €
Zema
0,40 €
Tirgus kapitalizācija
27,19 milj.
Vid. apjoms
187,71 tūkst.
Apjoms
119,78 tūkst.
Augstākā 52 ned.
1,04 €
Zemākā 52 ned.
0,29 €
Peļņa uz vienu akciju
-0,38 €
Apgrozībā esošās akcijas
72,59 milj.
Darbinieku skaits
228
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
Investor's Business Daily
·
pirms 29 minūtēm
Futures Loom; Nvidia Probes CEO Huang Espionage Reports
Yahoo! Finance Canada
·
pirms 54 minūtēm
CC,ANGX,CDNL,IDAI,AMRC,NTHI,CUEN,PRTS,LIEN,RGCO,DFH,SELF,TISI,EQPT,REFI,MTDR,GROV,BRID,RVSB,AFCG,SRTS,BGDE,PHIO,SKIL | Stock Prices | Quote Comparison - Yahoo Finance
Cryptonews.net
·
pirms 34 minūtēm
XRP Price Prediction: Analyst Warns of $0.80 Crash if S&P 500 Breaks Key Support
Bloomberg.com
·
pirms 1 dienas
Wall Street Strategists Call Stock Rout a Fresh Reason to Buy
Profils
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.
In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
Par “Novacyt SA”
ĢenerāldirektorsDavid Allmond
Darbinieki228
Dibināšanas datums2006. gada 3. jūl.
Galvenais birojs-
SektorsHealth Care
Nozare-
Tīmekļa vietnenovacyt.com